{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:57:36Z","timestamp":1772272656889,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00277-023-05516-8","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T09:02:13Z","timestamp":1698224533000},"page":"3401-3412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Higher expression of programmed cell death 4 (PDCD4) in acute myeloid leukemia is associated with better prognosis after chemotherapy"],"prefix":"10.1007","volume":"102","author":[{"given":"Hongwei","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianchuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0260-409X","authenticated-orcid":false,"given":"Kang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"5516_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377","journal-title":"Blood"},{"key":"5516_CR2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K et al (2022) Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell 40:850-864.e9","journal-title":"Cancer Cell"},{"key":"5516_CR3","doi-asserted-by":"publisher","first-page":"175883592092763","DOI":"10.1177\/1758835920927635","volume":"12","author":"N Zhang","year":"2020","unstructured":"Zhang N, Zhang Y, Zhang P, Lou S, Chen Y, Li H et al (2020) Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia. Ther Adv Med Oncol 12:1758835920927635","journal-title":"Ther Adv Med Oncol"},{"key":"5516_CR4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1200\/JCO.21.01422","volume":"40","author":"AH Elsayed","year":"2022","unstructured":"Elsayed AH, Cao X, Mitra AK, Wu H, Raimondi S, Cogle C et al (2022) Polygenic Ara-C response score identifies pediatric patients with acute myeloid leukemia in need of chemotherapy augmentation. J Clin Oncol 40:772\u2013783","journal-title":"J Clin Oncol"},{"key":"5516_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nm.4255","volume":"23","author":"C Schneider","year":"2017","unstructured":"Schneider C, Oellerich T, Baldauf H-M, Schwarz S-M, Thomas D, Flick R et al (2017) SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med 23:250\u2013255","journal-title":"Nat Med"},{"key":"5516_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s12276-022-00735-x","volume":"54","author":"N Zhang","year":"2022","unstructured":"Zhang N, Shen Y, Li H, Chen Y, Zhang P, Lou S et al (2022) The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability. Exp Mol Med 54:194\u2013205","journal-title":"Exp Mol Med"},{"key":"5516_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani D, Kumar A, Br\u00fcck O, Kontro M, Yadav B, Helles\u00f8y M et al (2022) Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov 12:388\u2013401","journal-title":"Cancer Discov"},{"key":"5516_CR8","doi-asserted-by":"publisher","first-page":"808475","DOI":"10.3389\/fonc.2022.808475","volume":"12","author":"S Ghafouri-Fard","year":"2022","unstructured":"Ghafouri-Fard S, Hussen BM, Mohaqiq M, Shoorei H, Baniahmad A, Taheri M et al (2022) Interplay between non-coding RNAs and programmed cell death proteins. Front Oncol 12:808475","journal-title":"Front Oncol"},{"key":"5516_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.freeradbiomed.2020.06.016","volume":"159","author":"K Lu","year":"2020","unstructured":"Lu K, Chen Q, Li M, He L, Riaz F, Zhang T et al (2020) Programmed cell death factor 4 (PDCD4), a novel therapy target for metabolic diseases besides cancer. Free Radic Biol Med 159:150\u2013163","journal-title":"Free Radic Biol Med"},{"key":"5516_CR10","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3892\/ijo.2016.3706","volume":"49","author":"W Wang","year":"2016","unstructured":"Wang W, Song X-W, Zhao C-H (2016) Roles of programmed cell death protein 5 in inflammation and cancer (Review). Int J Oncol 49:1801\u20131806","journal-title":"Int J Oncol"},{"key":"5516_CR11","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.3390\/cancers14235986","volume":"14","author":"J Liu","year":"2022","unstructured":"Liu J, Zhao K, Wu S, Li C, You C, Wang J et al (2022) The dual role of PDCD10 in cancers: a promising therapeutic target. Cancers (Basel) 14:5986","journal-title":"Cancers (Basel)"},{"key":"5516_CR12","doi-asserted-by":"publisher","first-page":"e001230","DOI":"10.1136\/jitc-2020-001230","volume":"9","author":"H Zha","year":"2021","unstructured":"Zha H, Jiang Y, Wang X, Shang J, Wang N, Yu L et al (2021) Non-canonical PD-1 signaling in cancer and its potential implications in clinic. J Immunother Cancer 9:e001230","journal-title":"J Immunother Cancer"},{"key":"5516_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6:38","journal-title":"Nat Rev Dis Primers"},{"key":"5516_CR14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398:1002\u20131014","journal-title":"Lancet"},{"key":"5516_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD (2022) First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol 40:586\u2013597","journal-title":"J Clin Oncol"},{"key":"5516_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrurol.2017.172","volume":"15","author":"RC Walshaw","year":"2018","unstructured":"Walshaw RC, Honeychurch J, Illidge TM, Choudhury A (2018) The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer. Nat Rev Urol 15:251\u2013259","journal-title":"Nat Rev Urol"},{"key":"5516_CR17","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1124\/pr.116.012682","volume":"68","author":"G Alatrash","year":"2016","unstructured":"Alatrash G, Daver N, Mittendorf EA (2016) Targeting immune checkpoints in hematologic malignancies. Pharmacol Rev 68:1014\u20131025","journal-title":"Pharmacol Rev"},{"key":"5516_CR18","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:2059\u20132074","journal-title":"N Engl J Med"},{"key":"5516_CR19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL et al (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562:526\u2013531","journal-title":"Nature"},{"key":"5516_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/bioinformatics\/btl567","volume":"23","author":"S Falcon","year":"2007","unstructured":"Falcon S, Gentleman R (2007) Using GOstats to test gene lists for GO term association. Bioinformatics 23:257\u2013258","journal-title":"Bioinformatics"},{"key":"5516_CR21","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K (2017) KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45:D353\u2013D361","journal-title":"Nucleic Acids Res"},{"key":"5516_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fphar.2019.00609","volume":"10","author":"D Liao","year":"2019","unstructured":"Liao D, Wang M, Liao Y, Li J, Niu T (2019) A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Front Pharmacol 10:609","journal-title":"Front Pharmacol"},{"key":"5516_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14737140.2019.1589374","volume":"19","author":"JP Bewersdorf","year":"2019","unstructured":"Bewersdorf JP, Stahl M, Zeidan AM (2019) Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert Rev Anticancer Ther 19:393\u2013404","journal-title":"Expert Rev Anticancer Ther"},{"key":"5516_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","volume":"13","author":"N Zhang","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G et al (2023) Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J 13:82","journal-title":"Blood Cancer J"},{"key":"5516_CR25","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/ijms22115789","volume":"22","author":"M-K Song","year":"2021","unstructured":"Song M-K, Park B-B, Uhm J-E (2021) Targeted therapeutic approach based on understanding of aberrant molecular pathways leading to leukemic proliferation in patients with acute myeloid leukemia. Int J Mol Sci 22:5789","journal-title":"Int J Mol Sci"},{"key":"5516_CR26","doi-asserted-by":"publisher","first-page":"7343","DOI":"10.1038\/s41598-019-43910-3","volume":"9","author":"Y An","year":"2019","unstructured":"An Y, Hu Y, Li X, Li Z, Duan J, Yang X-D (2019) Selection of a novel DNA aptamer against OFA\/iLRP for targeted delivery of doxorubicin to AML cells. Sci Rep 9:7343","journal-title":"Sci Rep"},{"key":"5516_CR27","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.18632\/oncotarget.27222","volume":"10","author":"T Kawase","year":"2019","unstructured":"Kawase T, Nakazawa T, Eguchi T, Tsuzuki H, Ueno Y, Amano Y et al (2019) Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells. Oncotarget 10:6111\u20136123","journal-title":"Oncotarget"},{"key":"5516_CR28","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.clml.2021.05.016","volume":"21","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Short NJ, Fathi AT, Marcucci G, Ravandi F, Tallman M et al (2021) Acute myeloid leukemia: historical perspective and progress in research and therapy over 5 decades. Clin Lymphoma Myeloma Leuk 21:580\u2013597","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5516_CR29","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.2147\/OTT.S218928","volume":"12","author":"N Zhang","year":"2019","unstructured":"Zhang N, Chen Y, Lou S, Shen Y, Deng J (2019) A six-gene-based prognostic model predicts complete remission and overall survival in childhood acute myeloid leukemia. Onco Targets Ther 12:6591\u20136604","journal-title":"Onco Targets Ther"},{"key":"5516_CR30","doi-asserted-by":"publisher","first-page":"847345","DOI":"10.3389\/fimmu.2022.847345","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Hong M, Li Y, Chen D, Wu Y, Hu Y (2022) Programmed cell death tunes tumor immunity. Front Immunol 13:847345","journal-title":"Front Immunol"},{"key":"5516_CR31","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s10495-022-01735-y","volume":"27","author":"S Kari","year":"2022","unstructured":"Kari S, Subramanian K, Altomonte IA, Murugesan A, Yli-Harja O, Kandhavelu M (2022) Programmed cell death detection methods: a systematic review and a categorical comparison. Apoptosis 27:482\u2013508","journal-title":"Apoptosis"},{"key":"5516_CR32","doi-asserted-by":"publisher","first-page":"808475","DOI":"10.3389\/fonc.2022.808475","volume":"12","author":"S Ghafouri-Fard","year":"2022","unstructured":"Ghafouri-Fard S, Hussen BM, Mohaqiq M, Shoorei H, Baniahmad A, Taheri M et al (2022) Interplay between non-coding RNAs and programmed cell death proteins. Front Oncol 12:808475","journal-title":"Front Oncol"},{"key":"5516_CR33","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/cam4.5025","volume":"12","author":"K Xu","year":"2023","unstructured":"Xu K, Fei W, Huo Z, Wang S, Li Y, Yang G et al (2023) PDCD10 promotes proliferation, migration, and invasion of osteosarcoma by inhibiting apoptosis and activating EMT pathway. Cancer Med 12:1673\u20131684","journal-title":"Cancer Med"},{"key":"5516_CR34","doi-asserted-by":"publisher","first-page":"531785","DOI":"10.3389\/fimmu.2020.531785","volume":"11","author":"X Zhou","year":"2020","unstructured":"Zhou X, Xing J, Tang X, Sheng X, Chi H, Zhan W (2020) Interleukin-2 (IL-2) interacts with IL-2 receptor beta (IL-2R\u03b2): its potential to enhance the proliferation of CD4+ T lymphocytes in flounder (Paralichthys olivaceus). Front Immunol 11:531785","journal-title":"Front Immunol"},{"key":"5516_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fphar.2019.00609","volume":"10","author":"D Liao","year":"2019","unstructured":"Liao D, Wang M, Liao Y, Li J, Niu T (2019) A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Front Pharmacol 10:609","journal-title":"Front Pharmacol"},{"key":"5516_CR36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3892\/ol.2021.12802","volume":"22","author":"H Zhou","year":"2021","unstructured":"Zhou H, Shi P, Jia X, Xue Q (2021) Long non-coding RNA LINC01018 inhibits the progression of acute myeloid leukemia by targeting miR-499a-5p to regulate PDCD4. Oncol Lett 22:541","journal-title":"Oncol Lett"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05516-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05516-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05516-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:06:03Z","timestamp":1699679163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05516-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5516"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05516-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"This article does not contain any studies with human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}